Life Technologies Introduces Its Most-Efficient, Versatile Reagent for Difficult-to-Transfect Cells
CARLSBAD, Calif., Jan. 17, 2014 -- Life Technologies Corporation today announces the launch of Lipofectamine® 3000, the company’s most efficient and versatile transfection reagent for nucleic acid delivery in the broadest spectrum of cell lines. The product increases efficiency up to 10-fold in difficult-to-transfect cells, which is key for researchers working with more biologically relevant cell models.
“Its superior transfection efficiency, coupled with the reduction of cytotoxicity-associated cell alteration, provides consistent results and more significant experiments,” said Rui Eduardo Castro, Ph.D., Av. Professor Gama Pinto, University of Lisbon, who studies the pathogenesis of human non-alcoholic liver disease (NAFLD). “This leads simply to better research.”
Working with biologically relevant cell models provides researchers with more meaningful answers to their research questions. The lack of lipid-based transfection products that efficiently transfect these cell types has challenged researchers for many years. To overcome these obstacles, Lipofectamine 3000 is designed to optimize every step in the transfection process and deliver superior performance and improved cell viability in hard-to-transfect cells researchers care about.
“The greatest benefit we’ve seen is its versatility. In some cases, it can even replace electroporation, which improves the power of experiments and the ability to make meaningful comparisons,” says Natasha Roark, Scientist, Synthetic Biology, Research and Development at Life Technologies. “Lipofectamine 3000 greatly simplifies my workflow, in part, because the viability that I’ve experienced post transfection has been much better. This allows me to get it right the first time.”
Uma Lakshmipathy, Ph.D., Principal Scientist, Cell Biology at Life Technologies, said: “Lipofectamine 3000 challenges the notion that reagent-based methods are ineffective in delivering large reprogramming vectors by enabling efficient reprogramming of skin fibroblasts with Life Technologies’ Epi5 Episomal iPSC Reprogramming Kit, therefore providing an easier and streamlined workflow for human iPSC generation.”
For more information on Lipofectamine 3000, visit: www.lifetechnologies.com/3000
Lipofectamine 3000 is for Research Use Only, not intended for diagnostic purposes.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.